UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
ZUSDURI's peak sales are anticipated at $1 billion by 2030, with a four-year ramp, but near-term revenue guidance will not be provided until at least Q2–Q3 2026. URGN's liquidity improved to $245.5 million after a revised Pharmakon loan, yet cash burn remains high and ZUSDURI's commercial success is critical for financial stability. Risks include ZUSDURI's market adoption, management execution, and patent protection, with regulatory exclusivity expiring in 2028 and key patents expiring in 2031. designer491/iStock via Getty Images This is my seventh UroGen Pharma ( URGN ) article, following 11/2025's "UroGen: Expect Rough Patch Before Strong Recovery In 2026". Knee-Deep in Its Rough Patch, Urogen's Stock is Moving Erratically Price chart As shown by its This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of URGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Ltd. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
URGN
Earnings
- 3/2/26 - Beat
URGN
Analyst Actions
- 3/2/26 - Oppenheimer Holdings, Inc.
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website